Overview
Ipamorelin Overview
Ipamorelin is a synthetic pentapeptide with the sequence Aib-His-D-2Nal-D-Phe-Lys-NH2. It was first reported in 1998 by a Novo Nordisk research group, who developed it from the earlier secretagogue GHRP-1. The chain carries two non-proteinogenic residues, 2-aminoisobutyric acid (Aib) at the N-terminus and D-2-naphthylalanine at its core, and ends in a C-terminal amide.
Ipamorelin is an agonist of the growth hormone secretagogue receptor (GHS-R1a), the same receptor that binds ghrelin. What sets it apart is selectivity. In preclinical rodent and swine models, it stimulated growth hormone secretion without raising ACTH or cortisol, even at concentrations far above its half-maximal response. That narrow profile makes it a useful reference compound for comparing receptor selectivity across the GHRP family. Laboratory work has also used it to study somatotroph signaling in pituitary cell preparations, periosteal bone formation in rodent models, and ghrelin receptor-mediated contractility in isolated gastric smooth muscle.
Each lot is made by solid-phase peptide synthesis, third-party tested, and supplied with a Certificate of Analysis.
| Sequence | Aib-His-D-2Nal-D-Phe-Lys-NH2 |
|---|---|
| Sequence length | 5 residues (pentapeptide, C-terminal amide) |
| Also known as | NNC 26-0161 |
| Molecular formula | C38H49N9O5 |
| Molecular weight | 711.85 g/mol |
| CAS number | 170851-70-4 |
| PubChem CID | 9831659 |
| Form | Lyophilized powder |
| Purity | [≥99% by HPLC, per COA] |
| Storage | -20°C, sealed and protected from light |
Certificate of Analysis
| Date | Lot | Certificate |
|---|---|---|
| Ipamorelin 10mgJun 11, 2026 | 260526IP103 | View COA |